Document is current
Any future updates will be listed below
-
Authors
Seneschal, Julien
Figueras Nart, lgnasi
Sabatino, Silvia
Papadimitropoulos, Manny
Dabral, Srishti
Lampropoulou, Anastasia
-
Funding
Funding for this research was provided by:
Eli Lilly Canada
- License Information
-
More Information
Article History
Received: 25 November 2024
Accepted: 14 April 2025
First Online: 16 May 2025
Declarations
:
: Julien Seneschal has received support for attending meetings and/or travel from Eli Lilly and Company, and consulting fees and payment or honoraria for lectures, presentations, speakers bureaus, abstract (and subsequent poster) writing, or educational events from AbbVie, Pfizer, Almirall, Eli Lilly and Company, and Sanofi. lgnasi Figueras Nart has received consulting fees, payment or honoraria for lectures, presentations, speakers bureaus, abstract (and subsequent poster) writing, or educational events, and support for attending meetings and/or travel from AbbVie, Eli Lilly and Company, Leo Pharma, Novartis, Pfizer, Regeneron, Sanofi, and Vifor Pharma. Manny Papadimitropoulos, Silvia Sabatino, and Srishti Dabral are employees and minor stakeholders of Eli Lilly and Company. Anastasia Lampropoulou is a former employee and former minor stakeholder of Eli Lilly and Company.
: This was a systematic review of the literature, so no ethical approval was required. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
